Lirentelimab
As of the edition of 20 October 2026, Lirentelimab is an antibody: stopped in 2024; acts on SIGLEC8.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Antibody
- Registered trials
- 14, 3 stopped early
- Disease areas
- Immune system; Blood and lymph; Digestive system; Skin and connective tissue; Cancer; Eye
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Lirentelimab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SIGLEC8 | Sialic acid-binding Ig-like lectin 8 | Q9NYZ4 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 5 | 3 | 0 | 2 |
| Phase 3 | 5 | 4 | 0 | 1 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Concentra Biosciences | Lead sponsor of trials | 2016 to now |